<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00636558</url>
  </required_header>
  <id_info>
    <org_study_id>V937-004</org_study_id>
    <secondary_id>PSX-X04</secondary_id>
    <nct_id>NCT00636558</nct_id>
  </id_info>
  <brief_title>Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)</brief_title>
  <acronym>PSX-X04</acronym>
  <official_title>A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak™ (Coxsackie Virus A21) Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 With or Without DAF Expressing Tumours (PSX-X04)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viralytics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viralytics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coxsackie A21 (CVA21) virus is to be administered by IV infusion to patients with Stage 4&#xD;
      melanoma, prostate and breast cancer. This is a dose escalation, safety study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, multiple dose, dose escalation, open label, cohort study of three&#xD;
      intravenous doses of Coxsackie virus A21 in patients with stage IV solid tumours. Prospective&#xD;
      patients will attend the study centre for initial screening within 28 days prior to&#xD;
      commencement of treatment. They will have the nature of the study and its procedures and&#xD;
      risks fully explained. Patients must then sign an informed consent form giving permission for&#xD;
      tumour testing before initial screening can be commenced.&#xD;
&#xD;
      Patients whose tumours test positive for ICAM-1 with or without DAF will attend the study&#xD;
      centre for a further screening visit within 14 days prior to commencement of treatment. They&#xD;
      will sign a full study informed consent form before any further screening procedures are&#xD;
      carried out.&#xD;
&#xD;
      Patients who satisfy all inclusion and none of the exclusion criteria will commence the&#xD;
      treatment stage, which consists of one or more doses of CVA21 administered by intravenous&#xD;
      infusion as per the dosage escalation chart. The first 4 cohorts will be treated as&#xD;
      in-patients. The follow up period will consist of 12 weeks, during which time patients will&#xD;
      attend the trial centre for up to13 follow up visits to collect safety and efficacy data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 29, 2008</start_date>
  <completion_date type="Actual">January 12, 2012</completion_date>
  <primary_completion_date type="Actual">January 12, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of the study is to determine the safety and tolerability of CVA21 given by intravenous infusion in multiple escalating doses.</measure>
    <time_frame>Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To obtain preliminary efficacy data, determine the time course of viraemia and its elimination post-administration of CVA21</measure>
    <time_frame>Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterise the time course of the anti-CVA21 antibody response</measure>
    <time_frame>Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Melanoma</condition>
  <condition>Breast Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>CVA21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV administration of CVA21 in a dose escalation manner</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVA21</intervention_name>
    <description>IV infusion, dose escalation of one or two infusions of escalating strength</description>
    <arm_group_label>CVA21</arm_group_label>
    <other_name>CAVATAK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are willing and able to provide written informed consent to participate&#xD;
             in the study.&#xD;
&#xD;
          2. Male or female aged 18 years or older.&#xD;
&#xD;
          3. Stage IV solid tumour disease with the primary tumour being any one of the following&#xD;
             types - breast, prostate or melanoma.&#xD;
&#xD;
          4. ICAM-1 with or without DAF-expressing tumour. Patients without archival material for&#xD;
             testing must agree to a new tumour biopsy.&#xD;
&#xD;
          5. Absence of circulating antibodies to CVA21 (titre &lt; 1:16).&#xD;
&#xD;
          6. Patients must have failed or refused standard treatment(s).&#xD;
&#xD;
          7. Adequate haematological, hepatic and renal function, defined as:&#xD;
&#xD;
               -  ANC &gt; 1.5 x 10^9/L, platelets &gt; 100 x 10^9/L&#xD;
&#xD;
               -  Bilirubin &lt; 20µmol/L, AST &lt; 2.5 times the upper limit of normal&#xD;
&#xD;
               -  Calculated creatinine clearance &gt; 30 mL/minute&#xD;
&#xD;
          8. Adequate immunologic function, defined as:&#xD;
&#xD;
               -  Serum IgG &gt; 5g/L&#xD;
&#xD;
               -  T cell subsets within normal limits&#xD;
&#xD;
          9. Fertile males and females must agree to the use of an adequate form of contraception.&#xD;
             Hormonal contraceptives should be supplemented with an additional barrier method.&#xD;
             Negative pregnancy test is required in female patients of child-bearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence or history of Central Nervous System (CNS) malignancy.&#xD;
&#xD;
          2. Patients must not have received chemotherapy within 4 weeks prior to date of consent.&#xD;
&#xD;
          3. Performance status &gt; 1 on the Eastern Cooperative Oncology Group (ECOG) scale.&#xD;
&#xD;
          4. Life expectancy &lt; 6 months.&#xD;
&#xD;
          5. Pregnancy or breastfeeding.&#xD;
&#xD;
          6. Primary or secondary immunodeficiency, including immunosuppressive disease, and&#xD;
             immunosuppressive doses of corticosteroids (e.g. prednisolone &gt; 7.5mg per day) or&#xD;
             other immunosuppressive medications including cyclosporine, azathioprine, interferons,&#xD;
             within the past 4 weeks.&#xD;
&#xD;
          7. Positive serology for HIV, hepatitis B or hepatitis C.&#xD;
&#xD;
          8. Splenectomy.&#xD;
&#xD;
          9. Presence of uncontrolled infection.&#xD;
&#xD;
         10. Presence of unstable neurological disease.&#xD;
&#xD;
         11. Any uncontrolled medical condition that in the opinion of the Investigator is likely&#xD;
             to place the patient at unacceptable risk during the study or reduce their ability to&#xD;
             complete the study&#xD;
&#xD;
         12. Participation in another study requiring administration of an investigational drug or&#xD;
             biological agent within the last 4 weeks&#xD;
&#xD;
         13. Known allergy to treatment medication or its excipients&#xD;
&#xD;
         14. Any other medical or psychological condition that would preclude participation in the&#xD;
             study or compromise ability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Chern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Redcliffe Hospital, Brisbane, Qld., Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Winston Liauw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St George Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Care Centre, St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redcliffe Hospital</name>
      <address>
        <city>Redcliffe</city>
        <state>Queensland</state>
        <zip>4020</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 7, 2008</study_first_submitted>
  <study_first_submitted_qc>March 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <last_update_submitted>June 26, 2019</last_update_submitted>
  <last_update_submitted_qc>June 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coxsackie virus</keyword>
  <keyword>melanoma</keyword>
  <keyword>breast cancer</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coxsackievirus Infections</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

